Our team of medical biologists is committed to delivering increasingly innovative and high-performing solutions every day to help meet your needs and support the best possible care for your patients with high level of accuracy.

As of July 1, 2025, Cerba is enhancing its tumor NGS testing offering to improve the identification of novel therapeutic targets and resistance mechanisms.

EXPANDED DNA NGS PANELS

Systematic interpretation of the tumor genotype across 42 genes for all cancer types, as well as BRCA1 and BRCA2 analysis for ovarian, prostate, breast, and pancreatic cancers.

Genes analyzed: AKT1, ALK, ATRX, BRAF, CDK4, CDK6, CDKN2A, CTNNB1, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, FOXL2, GNA11, GNAQ, GNAS, H3C2, H3C3, H3F3A, H3F3B, HRAS, IDH1, IDH2, KEAP1, KIT, KRAS, MAP2K1, MET, NRAS, PDGFRA, PIK3CA, POLD1, POLE, PTEN, RET, ROS1, SMARCA4, STK11, TERT, TP53
+/- BRCA1, BRCA2

A UNIQUE, INTEGRATED REPORT

All NGS results (DNA, RNA, and sWGS) generated from the same sample are consolidated into a single report, providing a comprehensive interpretation of the tumor genotype.

• Comprehensive overview of all available therapeutic options (approved indications,) together with their level of evidence (ESCAT scale).
• Systematic analysis of primary and acquired resistance mechanisms.

ACCESS THE NEW REPORT

SOMATIC ONCOGENETICS MEDICAL TEAM

Dr Marie-Magdelaine Coudé
Dr Guillaume Herbreteau
Dr Etienne Muller
onco@lab-cerba.com

Precision genomic medicine now provides personalized and essential therapeutic solutions to help treat cancer more rapidly and effectively.